suPAR measured using suPARnostic® TurbiLatex predicts critical illness and kidney failure in patients admitted to the intensive care unit Objective This prospective cohort study aimed to describe the role and feasibility of the prognostic [...]
suPAR: An exciting biomarker of systemic chronic inflammation. suPAR provides a more stable biomarker of systemic chronic inflammation than CRP or IL-6 and is less subject to the influence of acute infection and environmental [...]
New study: suPAR (cut-off levels ⩽4, 4-6, and ⩾6 ng/mL) can predict the need for mechanical ventilation and mortality in patients with COVID-19 symptoms. suPAR is a biomarker associated with adverse outcomes. This [...]
Measuring suPAR in COVID-19 patients presents a valuable tool for improving risk stratification accuracy and helping to predict the risk of developing severe consequences of a COVID-19 infection. This was confirmed in a newly [...]
A suPAR level below 4ng/ml can be a useful discharge marker. suPAR cut-offs <4, between 4-6 and >6ng/ml can identify acute medical patients who have low, medium or high risk of 30- and 90-day mortality. [...]
Nikaia Hospital was build in 1932 and became a general hospital in 1952 (Fig. 1). The hospital has 615 beds and more than 1,700 staff members. It is one of the largest hospitals in the Athens-Piraeus region, covering the [...]
Dr Vasileios Kaldis is trained as a surgeon and intensive care specialist consultant. Currently, he is heading the Emergency Department (ED) at the Sismanoglio General Hospital, located in the Northern part of Athens in Greece (Fig. 1). [...]
Early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in patients with moderate and severe COVID-19 pneumonia SAVE-MORE is a multicenter, double-blinded, randomised controlled trial in [...]
If you have any questions regarding our products or business, write to us here
New Webinar
